Your session is about to expire
← Back to Search
Biological/Vaccine: Bacillus Calmette-Guerin (BCG) for Alzheimer's Disease
Study Summary
This trial looks at whether the BCG vaccine could help people with Alzheimer's disease by looking at changes in cerebrospinal fluid and blood biomarkers.
- Alzheimer's Disease
- Dementia
- Mild Cognitive Impairment
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can people with the target ailment still participate in this research?
"Yes, this clinical trial is still recruiting patients. The latest information on the posting dates back to July 8th, 2022."
How can I enroll in this research project?
"Eligible participants for this study must have a diagnosis of Alzheimer's disease, be between 55-85 years old, and not have any other major health conditions. Currently, the trial is looking to recruit 15 more patients."
Can minors participate in this research trial?
"According to the eligibility criteria for this trial, the minimum age for participation is 55 and the maximum age is 85."
Does the FDA recognize Bacillus Calmette-Guerin (BCG) as a safe and effective vaccine?
"While Phase 2 trials lack the data to support efficacy, there is some evidence that Biological/Vaccine: Bacillus Calmette-Guerin (BCG) is safe. Our team at Power gave it a score of 2."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Share this study with friends
Copy Link
Messenger